EUVIMEDEUVIMED entdecken
Crossref

Novel N -(3-(1-(4-sulfamoylphenyl)triazol-4-yl)phenyl)benzamide Derivatives as Potent Carbonic Anhydrase Inhibitors with Broad-Spectrum Anticancer Activity: Leveraging Tail and Dual-Tail Approaches

Ashraf K El-Damasy, Hyun Ji Kim, Muhammad Faisal iD, Andrea Angeli iD, Ahmed E Elsawi, Wagdy M Eldehna iD, Claudiu T Supuran iD, Gyochang Keum iD

Journal of Medicinal Chemistry · 13.02.2025 · 68 (3) · 3764-3781

DOI: 10.1021/acs.jmedchem.4c02830 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 16.01.2025. Verfasst von Ashraf K El-Damasy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea. Hauptthemen laut MEDLINE: Carbonic Anhydrase Inhibitors, Antineoplastic Agents, Carbonic Anhydrases, Molecular Docking Simulation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Ministry of Food and Drug Safety, National Research Foundation of Korea, Korea Institute of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carbonic anhydrases (CAs) IX and XII are crucial for the survival and metastasis of solid tumors under hypoxic conditions. We designed compounds 7a-s, integrating triazole and benzenesulfonamide scaffolds known for inhibiting tumor-associated CAs IX/XII. Initial synthesis included compounds 7a-e, followed by diversification with small hydrophobic groups (7f-m) and hydrophilic heterocyclic secondary amines (7n-s). Compounds were evaluated against CA II, IX, and XII to assess activity and selectivity. Chlorinated derivative 7l exhibited the highest efficacy against CA IX (KI = 0.317 μM) and ditrifluoromethylated 7j against CA XII (KI = 0.081 μM). Subsequent testing on 60 cancer cell lines at 10 μM revealed promising anticancer activity, especially for dimethylated derivative 7h (CA IX, KI = 1.324 μM; CA XII, KI = 0.435 μM), with GI50 values ranging from 0.361 to 9.21 μM. Molecular docking analyses elucidated binding mechanisms, highlighting potential inhibitory actions of compound 7h on CAs IX and XII.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carbonic Anhydrase InhibitorsAntineoplastic AgentsCarbonic AnhydrasesMolecular Docking SimulationHumansStructure-Activity RelationshipCell Line, TumorDrug Screening Assays, AntitumorTriazolesBenzamidesCarbonic Anhydrase IXCell ProliferationAntigens, NeoplasmMolecular Structure

Substanzen

Carbonic Anhydrase InhibitorsAntineoplastic AgentsCarbonic AnhydrasesTriazolesBenzamidesCarbonic Anhydrase IXAntigens, Neoplasm

Autor:innen und Institutionen

  • Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
  • Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
  • Division of Bio-Medical Science and Technology, KIST School, University of Science and Technology, Seoul 02792, Republic of Korea.
  • Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico, Via U. Schiff 6, Sesto Fiorentino, Firenze 50019, Italy.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, P.O. Box, Kafrelsheikh 33516, Egypt.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Pharos University in Alexandria, Canal El Mahmoudia St., Alexandria 21648, Egypt.

ORCID-Profile: Muhammad Faisal, Andrea Angeli, Wagdy M Eldehna, Claudiu T Supuran, Gyochang Keum

Förderung

  • Ministry of Food and Drug Safety
  • National Research Foundation of Korea
  • Korea Institute of Science and Technology

Zitieren

APA

El-Damasy, A. K., Kim, H. J., Faisal, M., Angeli, A., Elsawi, A. E., Eldehna, W. M., Supuran, C. T., & Keum, G. (2025). Novel N -(3-(1-(4-sulfamoylphenyl)triazol-4-yl)phenyl)benzamide Derivatives as Potent Carbonic Anhydrase Inhibitors with Broad-Spectrum Anticancer Activity: Leveraging Tail and Dual-Tail Approaches. Journal of Medicinal Chemistry, 68(3), 3764-3781. https://doi.org/10.1021/acs.jmedchem.4c02830

Vancouver

El-Damasy AK, Kim HJ, Faisal M, Angeli A, Elsawi AE, Eldehna WM, et al. Novel N -(3-(1-(4-sulfamoylphenyl)triazol-4-yl)phenyl)benzamide Derivatives as Potent Carbonic Anhydrase Inhibitors with Broad-Spectrum Anticancer Activity: Leveraging Tail and Dual-Tail Approaches. Journal of Medicinal Chemistry. 2025;68(3):3764-3781. doi:10.1021/acs.jmedchem.4c02830

BibTeX
@article{ElDamasy2025,
  author = {El-Damasy, Ashraf K and Kim, Hyun Ji and Faisal, Muhammad and Angeli, Andrea and Elsawi, Ahmed E and Eldehna, Wagdy M and Supuran, Claudiu T and Keum, Gyochang},
  title = {Novel N -(3-(1-(4-sulfamoylphenyl)triazol-4-yl)phenyl)benzamide Derivatives as Potent Carbonic Anhydrase Inhibitors with Broad-Spectrum Anticancer Activity: Leveraging Tail and Dual-Tail Approaches},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {3},
  pages = {3764--3781},
  doi = {10.1021/acs.jmedchem.4c02830}
}
Kostenlos starten →